Product Theaters
The following information is subject to change.
A New Treatment Option for Patients with Acute Myeloid Leukemia
Sponsored by Bristol Myers Squibb
| Saturday, December 5, 2020, 11:00 a.m. - 12:00 p.m. Pacific time |
Speaker:
Michelle Little, PhD
Bristol Myers Squibb
Study Results from the First and Only Randomized Pivotal Trial in R/R DLBCL
Sponsored by Genentech
| Saturday, December 5, 2020, 11:00 a.m. - 12:00 p.m. Pacific time |
Speaker:
Lisa Musick, PharmD, BCPS
Genentech
Introducing BLENREP (belantamab mafodotin-blmf) for Injection, for Intravenous Use
Sponsored by GSK
| Saturday, December 5, 2020, 11:00 a.m. - 12:00 p.m. Pacific time |
Speaker:
Allison Doherty
GSK
A Discussion of Efficacy and Safety on a Treatment Option for Adults With Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)
Sponsored by Pfizer
| Saturday, December 5, 2020, 11:00 a.m. - 12:00 p.m. Pacific time |
Speaker:
Richa Shah, PharmD
Pfizer
Advances in the Treatment of aTTP
Sponsored by Sanofi Genzyme
| Saturday, December 5, 2020, 11:00 a.m. - 12:00 p.m. Pacific time |
Speaker:
Yu Chen Barrett, PhD
Sanofi Genzyme
NGS Solutions That Help Simplify Your Journey to Answers in Hemato-Oncology Research
Sponsored by Thermo Fisher Scientific
| Saturday, December 5, 2020, 11:00 a.m. - 12:00 p.m. Pacific time |
Speaker:
Amy Carroll, PhD
Thermo Fisher Scientific
A Targeted Therapeutic Approach for Relapsed or Refractory FLT3m+ AML Patients
Sponsored by Astellas Pharma US, Inc
| Sunday, December 6, 2020, 11:00 a.m. - 12:00 p.m. Pacific time |
Speaker:
Ramon V. Tiu, MD
Astellas Pharma US, Inc.
A Treatment Option for Patients with Myelodysplastic Syndromes
Sponsored by Bristol Myers Squibb
| Sunday, December 6, 2020, 11:00 a.m. - 12:00 p.m. Pacific time |
Speaker:
Jeffrey A. Jones, MD, MPH
Bristol Myers Squibb
Review of Efficacy and Safety of Monjuvi (tafasitamab-cxix) : FDA-Approved Monoclonal Antibody in Combination with Lenalidomide for Adult Patients with R/R DLBCL Who Have Received at Least One Prior Therapy
Sponsored by Incyte Corporation
| Sunday, December 6, 2020, 11:00 a.m. - 12:00 p.m. Pacific time |
Speaker:
Susan Snodgrass, MD
Incyte Corporation
Redefining Approaches in Early-Line Multiple Myeloma Treatment
Sponsored by Janssen Biotech, Inc
| Sunday, December 6, 2020, 11:00 a.m. - 12:00 p.m. Pacific time |
Speaker:
Kathleen Gray, PhD
Janssen Scientific Affairs
Developing the Future of CAR-T Cell Therapy Today
Sponsored by Novartis Pharmaceuticals
| Sunday, December 6, 2020, 11:00 a.m. - 12:00 p.m. Pacific time |
Speakers:
Amir Hefni, PhD
Novartis
Carolin Barth, MD
Novartis
A Treatment Option for Adult Patients With Newly Diagnosed CP Ph+ CML or Patients With CML Resistant/Intolerant to Prior TKI Therapy
Sponsored by Pfizer
| Sunday, December 6, 2020, 11:00 a.m. - 12:00 p.m. Pacific time |
Speaker:
Jasmeet Anand, PharmD
Pfizer
An Anti-CD38 Directed Antibody for the Treatment for Appropriate Patients with Relapsed Refractory Multiple Myeloma
Sponsored by Sanofi Genzyme
| Sunday, December 6, 2020, 11:00 a.m. - 12:00 p.m. Pacific time |
Speaker:
Megan Sell, NP
Sanofi Genzyme
Exploring Outcomes With Fixed-Duration Treatment in CLL and New Evidence in First-Line AML: Pivotal Clinical Trial Data That Supports Treatment Decisions and Patient Care
Sponsored by Abbvie
| Monday, December 7, 2020, 10:30 a.m. - 11:30 a.m. Pacific time |
Speaker:
R. Frank Cornell, MD, MS
AbbVie
clonoSEQ and MRD Assessment in the Management of Lymphoid Malignancies
Sponsored by Adaptive Biotechnologies
| Monday, December 7, 2020, 10:30 a.m. - 11:30 a.m. Pacific time |
Speaker:
Lanny R. Kirsch, MD
Adaptive Biotechnologies
PNH: Key Clinical Considerations for a Terminal Complement-Mediated Disease
Sponsored by Alexion Pharmaceuticals
| Monday, December 7, 2020, 10:30 a.m. - 11:30 a.m. Pacific time |
Speaker:
Anita Hill, MD, PhD
Alexion Pharmaceuticals, Inc.
Scientific Exploration of Novel Targets for Hematology: A Glimpse into Areas of Research and Development
Sponsored by AstraZeneca
| Monday, December 7, 2020, 10:30 a.m. - 11:30 a.m. Pacific time |
Speakers:
Katharina Modelska, MD, PhD
FibroGen
Anas Younes, MD
AstraZeneca
Priti Patel, MD
AstraZeneca
Andrew Mortlock, PhD
AstraZeneca
Raoul Tibes, MD, PhD
AstraZeneca
Farzana Walcott
AstraZeneca
Epcoritamab, a Novel Subcutaneous Bi-Specific CD3xCD20 Antibody for the Treatment of Patients with B-NHL: From Bench to Bedside and Beyond
Sponsored by Genmab
| Monday, December 7, 2020, 10:30 a.m. - 11:30 a.m. Pacific time |
Speaker:
Tahamtan Ahmadi, MD, PhD
Genmab US, Inc
Trust the Experience of a rFVIIa Product Used for a Wide Range of Indications
Sponsored by Novo Nordisk
| Monday, December 7, 2020, 10:30 a.m. - 11:30 a.m. Pacific time |
Speaker:
Stephanie Seremetis, MD
Novo Nordisk
IMBRUVICA® in Frontline CLL/SLL: A Case-based Approach
Sponsored by Pharmacyclics LLC, An AbbVie Company
| Monday, December 7, 2020, 10:30 a.m. - 11:30 a.m. Pacific time |
Speaker:
Imran Khan, MD
Janssen Biotech, Inc.